Callio Therapeutics
Callio Therapeutics develops dual-payload antibody-drug conjugates (ADCs) for people with cancer, including patients with tumors that have developed resistance to existing therapies. Its platform pairs synergistic drug payloads and uses a proprietary linker to design targeted treatments intended to overcome resistance and deliver more durable responses.
Facts
- HQ
- Seattle, WA, USA
- Sectors
- Biotechnology Research
- Founded
- 2025
- Employees
- 24
- Stage
- Series A
Is this your organization? Claim it
Callio Therapeutics Wins Best New ADC Drug Developer, Showcases Dual-Payload ADCs and Clinical Lead CLIO-8221 (first patient dosed March 2026)
Callio Therapeutics won Best New ADC Drug Developer at the 13th World ADC Awards and presented five sessions at World ADC San Diego 2026, highlighting its dual-payload ADC platform and clinical lead CLIO-8221, which dosed its first patient in March 2026.
Callio Therapeutics Appoints Zachary Hornby as CEO; Co-Founder Piers Ingram Moves to Senior Advisor
Callio Therapeutics named veteran biotech executive Zachary Hornby as CEO to lead advancement of its dual-payload antibody-drug conjugates (ADCs) through clinical development, while co-founder Piers Ingram becomes Senior Advisor and Jerome Boyd-Kirkup shifts to Senior Scientific Advisor.
Callio Therapeutics to Present Phase 1 Trial Design of CLIO-8221, a First-in-Class HER2 Dual-Payload ADC, at ASCO 2026
Callio Therapeutics will present the Phase 1 trial design for CLIO-8221, a first-in-class dual-payload HER2-targeted ADC combining a topoisomerase 1 inhibitor and an ATR inhibitor, at ASCO 2026 while the trial is actively enrolling patients with advanced HER2-expressing solid tumors.
People
See all 8-
Jerome Boyd-Kirkup Co-Founder
-
Piers Ingram Co-Founder
-
Chris Hassig Executive, Chief Scientific Officer